Literature DB >> 21790828

Human glioblastoma stem-like cells are more sensitive to allogeneic NK and T cell-mediated killing compared with serum-cultured glioblastoma cells.

Tony Avril1, Elodie Vauleon, Abderrahmane Hamlat, Stéphan Saikali, Amandine Etcheverry, Caroline Delmas, Sylma Diabira, Jean Mosser, Véronique Quillien.   

Abstract

Glioblastoma multiforme (GBM) is the most dramatic primary brain cancer with a very poor prognosis because of inevitable disease recurrence. The median overall survival is less than 1 year after diagnosis. Cancer stem cells have recently been disclosed in GBM. GBM stem-like cells (GSCs) exhibit resistance to radio/chemotherapeutic treatments and are therefore considered to play an important role in disease recurrence. GSCs are thus appealing targets for new treatments for GBM patients. In this study, we show that GBM cells with stem cell characteristics are resistant to lysis mediated by resting natural killer (NK) cells because of the expression of MHC class I molecules. However, GSCs are killed by lectin-activated NK cells. Furthermore, in experiments using the therapeutic antibody CetuximAb, we show that GSCs are sensitive to antibody-mediated cytotoxicity. We confirm the sensitivity of GSC to cytotoxicity carried out by IL2-activated NK cells and tumor-specific T cells. More importantly, we show that GSCs are more sensitive to NK and T cell-mediated lysis relatively to their corresponding serum-cultured GBM cells obtained from the same initial tumor specimen. Altogether, these results demonstrate the sensitivity of GSC to immune cell cytotoxicity and, therefore, strongly suggest that GSCs are suitable target cells for immunotherapy of GBM patients.
© 2011 The Authors. Brain Pathology © 2011 International Society of Neuropathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21790828     DOI: 10.1111/j.1750-3639.2011.00515.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  38 in total

Review 1.  Glioblastoma cancer stem-like cells: implications for pathogenesis and treatment.

Authors:  Edjah Kweku-Ebura Nduom; Costas George Hadjipanayis; Erwin G Van Meir
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.

Authors:  Andrea Gras Navarro; Justyna Kmiecik; Lina Leiss; Mateusz Zelkowski; Agnete Engelsen; Øystein Bruserud; Jacques Zimmer; Per Øyvind Enger; Martha Chekenya
Journal:  J Immunol       Date:  2014-11-07       Impact factor: 5.422

3.  Immunobiology and signaling pathways of cancer stem cells: implication for cancer therapy.

Authors:  Mohamed L Salem; Ahmed S El-Badawy; Zihai Li
Journal:  Cytotechnology       Date:  2014-12-17       Impact factor: 2.058

4.  ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells.

Authors:  Esen Yonca Bassoy; Atsuko Kasahara; Valentina Chiusolo; Guillaume Jacquemin; Emma Boydell; Sebastian Zamorano; Cristina Riccadonna; Serena Pellegatta; Nicolas Hulo; Valérie Dutoit; Madiha Derouazi; Pierre Yves Dietrich; Paul R Walker; Denis Martinvalet
Journal:  EMBO J       Date:  2017-03-10       Impact factor: 11.598

5.  Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent medulloblastoma and ependymoma.

Authors:  Soumen Khatua; Laurence J N Cooper; David I Sandberg; Leena Ketonen; Jason M Johnson; Michael E Rytting; Diane D Liu; Heather Meador; Prashant Trikha; Robin J Nakkula; Gregory K Behbehani; Dristhi Ragoonanan; Sumit Gupta; Aikaterini Kotrotsou; Tagwa Idris; Elizabeth J Shpall; Katy Rezvani; Rivka Colen; Wafik Zaky; Dean A Lee; Vidya Gopalakrishnan
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

6.  NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.

Authors:  Erik Ames; Robert J Canter; Steven K Grossenbacher; Stephanie Mac; Mingyi Chen; Rachel C Smith; Takeshi Hagino; Jessica Perez-Cunningham; Gail D Sckisel; Shiro Urayama; Arta M Monjazeb; Ruben C Fragoso; Thomas J Sayers; William J Murphy
Journal:  J Immunol       Date:  2015-09-11       Impact factor: 5.422

7.  Cyclopamine cooperates with EGFR inhibition to deplete stem-like cancer cells in glioblastoma-derived spheroid cultures.

Authors:  Sandrine Eimer; Frédéric Dugay; Kelly Airiau; Tony Avril; Véronique Quillien; Marc-Antoine Belaud-Rotureau; Francis Belloc
Journal:  Neuro Oncol       Date:  2012-10-26       Impact factor: 12.300

Review 8.  Positive and negative regulation by NK cells in cancer.

Authors:  Can M Sungur; William J Murphy
Journal:  Crit Rev Oncog       Date:  2014

9.  Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity.

Authors:  Gabriele Cantini; Federica Pisati; Sara Pessina; Gaetano Finocchiaro; Serena Pellegatta
Journal:  Oncoimmunology       Date:  2012-09-01       Impact factor: 8.110

10.  An overview of therapeutic approaches to brain tumor stem cells.

Authors:  Alireza Khoshnevisan
Journal:  Med J Islam Repub Iran       Date:  2012-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.